Finance

Lists
ZBIO:NASDAQ
Zenas Biopharma Inc
$28.86
+1.02%
(+0.29) 1D
Nov 10, 10:43:06 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
$28.22
High
$29.89
Low
$28.10
Mkt. cap
1.96B
Avg. vol.
583.46K
Volume
26.62K
52-wk high
$44.60
52-wk low
$13.50
EPS
-$9.40
Shares outstanding
67.82M
No. of employees
167
Open
$28.22
High
$29.89
Low
$28.10
Mkt. cap
1.96B
Avg. vol.
583.46K
Volume
26.62K
52-wk high
$44.60
52-wk low
$13.50
EPS
-$9.40
Shares outstanding
67.82M
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitezenasbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current $28.86
$55.00 (+90.58%)
Average
$44.80 (+55.23%)
Lowest
$32.00 (+10.88%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$44.00
+52.5%
11/09/2026
Chris Yu
Morgan Stanley
Hold
Maintained
$32.00
+10.9%
11/06/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$45.00
+55.9%
11/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$55.00
+90.6%
11/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$55.00
+90.6%
10/28/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$48.00
+66.3%
10/27/2026
Martin Fan
Wedbush
Buy
Maintained
$45.00
+55.9%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$32.00
+10.9%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
$45.00
+55.9%
08/14/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$44.00
+52.5%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$55.00
+90.6%
03/17/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$1.23 / -$1.27
+3.08%beat
Revenue / Est. (USD)
10.00M / 0.00
+∞%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
1.00M
10.00M
Cost of goods sold
55.72M
60.44M
62.91M
58.47M
Cost of revenue
55.72M
60.44M
62.91M
58.47M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.59M
16.91M
15.75M
27.44M
Operating expense
15.59M
16.91M
15.75M
27.44M
Total operating expenses
71.31M
77.35M
78.66M
85.91M
Operating income
-71.31M
-77.35M
-77.66M
-75.91M
Other non operating income
-7.48M
-24.00K
16.00K
-40.00K
EBT including unusual items
-240.34M
-80.99M
-111.34M
-108.87M
EBT excluding unusual items
-73.66M
-80.99M
-81.34M
-81.37M
Income tax expense
106.00K
-
114.00K
49.00K
Effective tax rate
-0.04%
-
-0.10%
-0.04%
Other operating expenses
-
-
-
-
Net income
-240.44M
-80.99M
-111.46M
-108.92M
Net profit margin
-
-
-11,145.60%
-1,089.23%
Earnings per share
-1.39
-1.46
-1.77
-1.23
Interest and investment income
12.15M
3.02M
6.60M
5.80M
Interest expense
-7.33M
-6.63M
-10.30M
-11.22M
Net interest expenses
4.82M
-3.61M
-3.70M
-5.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-71.30M
-77.34M
-77.66M
-75.90M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps